The present invention relates to immunoglobulin single variable domain sequences that are directed against (as defined herein) OX40L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such immunoglobulin single variable domain sequences. In particular these immunoglobulin single variable domain sequences can block binding of OX40L to OX40. The immunoglobulin single variable domains, compounds and constructs can be used for prophylactic, therapeutic or diagnostic purposes, such as for the treatment of inflammatory disease and/or disorder such as e.g. asthma, allergic asthma, chronic colitis, Crohn's disease, inflammatory bowel disease, and/or arthrosclerosis.

The present inventors discovered that problems of existing antibody pharmaceuticals can be solved by producing antigen-binding molecules that contain an antigen-binding domain whose antigen-binding activity varies depending on the concentration of a target tissue-specific compound. Use of antigen-binding molecules of the present invention enables various diseases that originate from a target tissue to be treated in a manner specific to the target tissue.

A new, stable trimeric TNFα structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNFα/TNFR1 interaction. Membrane-bound TNFα is not affected in its ability to signal through TNFR2, and thus the new structure of TNFα may be used in therapies which do not significantly raise the risk of infection or malignancy.

The present invention relates generally methods and kits for detecting binding interactions, in particular protein-protein interactions, and particularly to high throughput methods for labelling, analysing, detecting and measuring protein-protein interactions.

The present disclosure relates to a use of JULGI in diagnosing and treating guanine quadruplex-related disease and, more particularly, to a guanine-quadruplex (G-quadruplex) detecting composition comprising JULGI protein or a protein having a homology of 80% or higher to the JULGI protein, a diagnostic composition comprising the detecting composition, a diagnostic kit comprising the diagnostic composition, a method for providing information for diagnosis of a neurodegenerative disease, cancer, or a viral infection disease which are in pathological correlation with G-quadruplex, and a pharmaceutical composition for prevention or treatment of a neurodegenerative disease, cancer, or a viral infection disease, the pharmaceutical composition comprising JULGI protein, a protein having a homology of 80% or more with the JULGI protein, or a mutant protein thereof. Thanks to the activity of binding to the G-quadruplex structure, JULGI according to the present disclosure is expected to be advantageously used in diagnosing or treating various diseases that are in pathological correlation with the abnormal formation and dissociation of the G-quadruplex structure.

Compounds that may selectively inhibit Oplophorus luciferase-derived bioluminescent complexes, e.g., NanoBiT® bioluminescent complex, are disclosed as well as compositions and kits comprising the compounds, and methods of using the compounds.

The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.

Methods are disclosed for identifying one or more proteins or polypeptides comprised by a sample. The methods comprise determining binding of each polypeptide with respect to each binding pool of a plurality of binding pools, wherein each binding pool comprises one or more probes which bind a structure comprised by a protein or polypeptide. In some aspects, polypeptides can be denatured and separated into individual polypeptide strands and immobilized on a solid support prior to determining binding of the binding pools. A protein, polypeptide or polypeptide strand can be identified by searching, in at least one database, for a protein or polypeptide sequence comprising binding pool targets either identical to or most similar to the binding pool targets comprised by the protein, polypeptide or polypeptide strand to be identified. Kits for identifying proteins, polypeptides and polypeptide strands are also disclosed.

Kits and methods of using the kits for analyzing macromolecules, including peptides, polypeptides, and proteins, employing nucleic acid encoding are disclosed. The sample analysis kits employ nucleic acid encoding and/or nucleic acid recording of a molecular interaction and/or reaction, such as recognition events (e.g., between an antigen and an antibody, between a modified terminal amino acid residue, or between a small molecule or peptide therapeutic and a target, etc.). Additional barcoding reagents, such as those for cycle-specific barcoding (e.g., “clocking”), compartment barcoding, combinatorial barcoding, spatial barcoding, or any combination thereof, may be included in the kits. The sample may comprise macromolecules, including peptides, polypeptides, and proteins, and the recording may generate molecular interaction and/or reaction information, and/or polypeptide sequence information. The kits may be used in high-throughput, multiplexed, and/or automated analysis, and are suitable for analysis of a proteome or subset thereof.

The present invention relates to a method of determining the capacity of a Cluster 1 mammalian Transcription Factor (TF) for phase separation and/or the capacity for forming a transcriptional condensate in a sample, including a method of determining the presence, localization and/or morphology of a transcriptional condensate comprising said Transcription Factor, and/or of determining the composition of a transcriptional condensate comprising at least one Cluster 1 mammalian TF and/or of determining the transcriptional activity of the TF or a condensate comprising the TF. Further, the present invention relates to an active agent for use in a method of preventing and/or treating a disorder associated with, caused by and/or accompanied with a dysfunction of a biomolecular condensate comprising at least one Cluster 1 mammalian TF.